Verapamil and beta cell function in adults with recent-onset type 1 diabetes

Pancreatic beta cell loss is a key factor in the pathogenesis of type 1 diabetes (T1D), but therapies to halt this process are lacking. We previously reported that the approved antihypertensive calcium-channel blocker verapamil, by decreasing the expression of thioredoxin-interacting protein, promot...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Nature medicine Ročník 24; číslo 8; s. 1108 - 1112
Hlavní autoři:	Ovalle, Fernando, Grimes, Tiffany, Xu, Guanlan, Patel, Anish J., Grayson, Truman B., Thielen, Lance A., Li, Peng, Shalev, Anath
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	New York Nature Publishing Group US 01.08.2018 Nature Publishing Group
Témata:	692/163 692/163/2743/137 692/308/2779/777 692/308/575 Adult Adults Antihypertensive agents Antihypertensives Beta cells Biomedical and Life Sciences Biomedicine Blood Pressure - drug effects Calcium Calcium channels Cancer Research Care and treatment Clinical trials Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 1 - pathology Diabetes Mellitus, Type 1 - physiopathology Diabetes therapy Diabetics Glucose Health aspects Heart Rate - drug effects Humans Infectious Diseases Insulin Insulin - metabolism Insulin-Secreting Cells - drug effects Insulin-Secreting Cells - pathology Letter Metabolic Diseases Molecular Medicine Neurosciences Pancreas Pancreatic beta cells Pathogenesis Peptides Proteins Risk factors Thioredoxin Thioredoxins Type 1 diabetes Type 2 diabetes Verapamil Verapamil - pharmacology Verapamil - therapeutic use
ISSN:	1078-8956, 1546-170X, 1546-170X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!